Pay in 4 interest-free payments of $7.37 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Insight #2 The Five-Factor Mental Model: What Really Drives a Drugs Success
No scheduling hassles
The purchaser and handling laboratory assume full responsibility for proper handling, storage, use, and disposal in accordance with all applicable local, state, and federal regulations
About ATTAIN-1, ATTAIN-2 and ATTAIN clinical trial program ATTAIN-1 (NCT05869903) is a Phase 3, 72-week, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of Foundayo 5.5 mg, 9 mg and 17.2 mg as a monotherapy to placebo in adults with obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease, who did not have diabetes
.jpeg?w=1500&h=1000)
